Nodular lichen myxoedematous: a new adverse event associated with ustekinumab.
Trinidad Montero-VílchezAntonio Martinez-LopezCarlos Cuenca-BarralesAurelio Martin-CastroMolina-Leyva AlejandroSalvador Arias-SantiagoPublished in: The Australasian journal of dermatology (2020)
Nodular lichen myxoedematosus is a localised form of lichen myxoedematosus, a chronic idiopathic cutaneous mucinosis of known aetiology. Ustekinumab is a human interleukin-12/23 monoclonal antibody that could directly or indirectly increase mucin production. Herein, we report for the first time a case of nodular lichen myxoedematosus associated with ustekinumab.